Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07MPL
|
|||
| Former ID |
DCL000231
|
|||
| Drug Name |
SNX-5422
|
|||
| Synonyms |
908115-27-5; PF-04929113; SNX-5422; SNX 5422; SNX5422; UNII-BF52J69Q8T; PF 04929113; PF-04929113 (SNX-5422); BF52J69Q8T; PF04929113; PF-4929113; cc-40; MLS006011083; SCHEMBL1220791; SCHEMBL1220790; CHEMBL1195136; SCHEMBL15604989; DTXSID50238270; C25H30F3N5O4; MolPort-023-293-502; BCPP000065; HMS3656B09; EX-A2343; BCP02427; s2656; ZINC95616595; ABP000737; ZINC100071931; ZINC252517142; AKOS027276395; SB16643; DB06070; API0008143; RL05706; SNX-5422 /; CS-0272; NCGC00346640-01; NCGC00386184-02; Glycine, trans-4-((2-(aminocarbonyl)-5-(4,5,6,7-tetrah
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Haematological malignancy [ICD-11: 2B33.Y] | Phase 1/2 | [1] | |
| Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Phase 1/2 | [1] | ||
| Chronic lymphocytic leukaemia [ICD-11: 2A82.0; ICD-10: C83.0, C91.1] | Phase 1 | [1] | ||
| Neuroendocrine cancer [ICD-11: 2B72.1; ICD-9: 209] | Phase 1 | [1] | ||
| Company |
Serenex
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H30F3N5O4
|
|||
| Canonical SMILES |
CC1(CC2=C(C(=O)C1)C(=NN2C3=CC(=C(C=C3)C(=O)N)NC4CCC(CC4)OC(=O)CN)C(F)(F)F)C
|
|||
| InChI |
1S/C25H30F3N5O4/c1-24(2)10-18-21(19(34)11-24)22(25(26,27)28)32-33(18)14-5-8-16(23(30)36)17(9-14)31-13-3-6-15(7-4-13)37-20(35)12-29/h5,8-9,13,15,31H,3-4,6-7,10-12,29H2,1-2H3,(H2,30,36)
|
|||
| InChIKey |
AVDSOVJPJZVBTC-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 908115-27-5
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hema... Blood. 2009 Jan 22;113(4):846-55. | |||
| REF 3 | Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol. 2008 Aug;8(4):370-4. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.